Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combining 123I-MIBG SPECT-CT radiomics and clinical factors
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new radiomics nomogram using 123I-metaiodobenzylguanidine (MIBG) SPECT-CT accurately predicts event-free survival in high-risk neuroblastoma. This tool aids in personalized prognosis and treatment decisions, potentially improving patient outcomes.
Area Of Science
- Oncology
- Radiology
- Medical Imaging
Background
- Accurate event-free survival (EFS) prediction is crucial for guiding treatment decisions in high-risk neuroblastoma.
- Optimizing therapy based on EFS can minimize side effects and improve patient survival.
Purpose Of The Study
- To develop and validate a radiomics nomogram using 123I-metaiodobenzylguanidine (MIBG) SPECT-CT.
- To evaluate its efficacy in predicting EFS after remission induction in high-risk neuroblastoma.
Main Methods
- Retrospective review of 87 high-risk neuroblastoma patients undergoing 123I-MIBG SPECT-CT.
- Extraction and analysis of radiomics features from SPECT-CT images.
- Construction of radiomics, clinical, and combined nomogram models.
Main Results
- The radiomics model (11 features) outperformed the clinical model in predicting EFS (C-indices up to 0.780 vs. 0.653).
- The combined radiomics nomogram demonstrated the best predictive performance (C-indices up to 0.819).
- The nomogram showed strong predictive accuracy in both training and validation cohorts.
Conclusions
- 123I-MIBG SPECT-CT-based radiomics accurately predicts EFS in high-risk neuroblastoma.
- The developed nomogram facilitates individualized prognosis assessment.
- This tool can assist clinicians in optimizing treatment and follow-up strategies, potentially enhancing patient survival.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.